# N4 Pharma granting of patent application in the United States

- Link: https://www.directorstalkinterviews.com/n4-pharma-granting-of-patent-application-in-the-united-states/4121124231
- Published: 2023-07-25T07:17:47+01:00
- Author: Ethan Davis

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has announced two
operational updates.

**Granting of further US patent**

The University of Queensland has informed the Company that it has been notified 
by the US patent attorney of the granting of its further patent application in relation
to Nuvec® in the United States.

N4 Pharma has licensed the exclusive worldwide rights to Nuvec® from the University
of Queensland for therapeutic uses in humans and animals.

This granted patent in the US is for the composition of matter of the nanoparticle
itself and will sit alongside the first US patent grant announced on 31 January 
2022, which concerned how the nanoparticle is made using a broad description of 
the manufacturing process used by the Company.

**Board Change**

The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring
from the Board for personal reasons. Chris Britten, currently a Non-Executive Director
of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with
effect from 1 August 2023. 

The Company will initiate a search process to identify an additional Non-Executive
Director and will provide an update as and when appropriate.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “We are delighted to receive notification of this further patent grant for our
> licensed patent in this critical and influential market.
> “The granting of this patent now means the patents in the US are on equal terms
> to those granted in other territories for both the particle itself and how it 
> is made.
> “On behalf of the Board, I would like to thank John for his contributions as Chairman
> of the Company over the last few years and we wish him all the best for the future.”

Share on: